Ранние стадии ХБП: проблематика и перспективы


DOI: https://dx.doi.org/10.18565/nephrology.2019.1.73-81

Е.Г. Дорофеева

ФГАОУ ВО «Российский университет дружбы народов»; Москва, Россия; ГБУЗ «Городская клиническая больница № 52 ДЗМ»; Москва, Россия
ХБП занимает третье место среди хронических патологий по смертности и вызываемым осложнениям. Проблематика ХБП носит не только медицинский, но и экономический характер. Гиперлипидемия, артериальная гипертензия, минерально-костные нарушения – это те факторы, которые хорошо поддаются контролю и лечению на ранних стадиях заболеваний почек. Ранняя диагностика и своевременное лечение осложнений способствуют не только улучшению качества жизни, но и снижению инвалидизации, смертности и экономических затрат.
В данном литературном обзоре представлены проблемы ранних стадий ХБП и проанализированы исследования последних лет.
Ключевые слова: экономика ХБП, ХБП ранних стадий, минерально-костные нарушения, гиперлипидемия, вторичный гиперпаратиреоз, артериальная гипертензия
Полный текст статьи доступен
в "Библиотеке Врача"

Литература

  1. Ward B.W., Schiller J.S., Goodman R.A. Multiple chronic conditions among US adults: a 2012 update. Prev. Chronic Dis. 2014;11:E62.
  2. Alwan A., Maclean D.R., Riley L.M., et al. Monitoring and surveillance of chronic noncommunicable diseases: progress and capacity in high-burden countries. Lancet. 2010;376:1861-1868. Doi: 10.1016/S0140-6736(10)61853-3.
  3. Robert Wood Johnson Foundation. Chronic Care: Making the Case for Ongoing Care. Available at: http://www.rwjf.org/content/dam/ farm/reports/reports/2010/rwjf5458. Accessed November 17, 2014.
  4. Coresh J., Astor B.C., Greene T., Eknoyan G., Levey A.S. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: third national health and nutrition examination survey. Am. J. Kidney Dis. 2003;41(1):1–12. Doi: 10.1053/ajkd.2003.50007.
  5. Demoulin N., Beguin C., Labriola L., Jadoul M. Preparing renal replacement therapy in stage 4 CKD patients referred to nephrologists: a difficult balance between futility and insufficiency. A cohort study of 386 patients followed in Brussels. Nephrol. Dial. Transpl. 2011;26:220–226. Doi: 10.1093/ndt/gfq372.
  6. O’Hare A.M., Choi A.I., Bertenthal D., et al. Age affects outcomes in chronic kidney disease. J. Am. Soc. Nephrol. 2007;18(10):2758–2765. Doi: 10.1681/ASN.2007040422.
  7. Evans M., Fryzek J.P., Elinder C.G., et al. The natural history of chronic renal failure: results from an unselected, population-based, inception cohort in Sweden. Am. J. Kidney Dis. 2005;46(5):863–870. Doi: 10.1053/j.ajkd.2005.07.040.
  8. Sud M., Tangri N., Levin A., Pintilie M., Levey A.S., Naimark D.M. CKD stage at nephrology referral and factors influencing the risks of ESRD and death. Am. J. Kidney Dis. 2014;63(6):928–936. Dоi: 10.1053/j.ajkd.2013.12.008.
  9. Levey A.S., Eckardt K.U., Tsukamoto Y., et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67(6):2089. Doi: 10.1111/j.1523-1755.2005.00365.x
  10. United States Renal Data System. USRDS 2014 Annual Data Report: Atlas of chronic kidney disease and end-stage renal disease in the United States. Available at: http://www.usrds.org. Accessed February 6, 2016.
  11. The revised Medicare Physician Fee Schedule Fact Sheet. http:// www.cms.gov/Outreach-and-Education/Medicare-Learning-NetworkMLN/MLNProducts/downloads/MedcrePhysFeeSchedfctsht.pdf. Accessed December 15, 2015.
  12. Swaminathan S., Mor V., Mehrotra R., Trivedi A. Medicare’s payment strategy for end-stage renal disease now embraces bundled payment and pay-for-performance to cut costs. Health Aff. (Millwood). 2012;31(9):2051–2058. Doi: 10.1377/hlthaff.2012.0368.
  13. Ягудина Р.И., Серпик В.Г., Абдрашитова Г.Т., Котенко О.Н. Экономическое бремя Хронической Болезни Почек в Российской Федерации. Фармакоэкономика: Теория и практика. 2014;4(2).
  14. Moorhead J.F., Chan M.K., El-Nahas M., Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet. 1982;2:1309–1311.
  15. Treatment of Hyperlipidemia Changes With Level of Kidney Function Rationale Shubha Ananthakrishnan and George A. Kaysen Advances in Chronic Kidney Disease. 2016;4(23):247–254.
  16. Muntner P., He J., Astor B.C., Folsom A.R., Coresh J. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J. Am. Soc. Nephrol. 2005;16(2):529–538. Doi: 10.1681/ASN.2004080656.
  17. Tonelli M., Muntner P., Lloyd A., et al. Association between LDL-C and risk of myocardial infarction in CKD. J. Am. Soc. Nephrol. 2013;24(6):979–986. Doi: 10.1681/ASN.2012080870.
  18. Tonelli M., Keech A., Shepherd J., et al. Effect of pravastatin in people with diabetes and chronic kidney disease. J. Am. Soc. Nephrol. 2005;16(12):3748–3754. Doi: 10.1681/ASN.2005070779.
  19. Tonelli M., Isles C., Curhan G.C. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation. 2004;110(12):1557–1563. Doi: 10.1161/01.CIR.0000143892.84582.60.
  20. Colhoun H.M., Betteridge D.J., Durrington P.N., et al. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am. J. Kidney Dis. 2009;54(5):810–819. Doi: 10.1053/j.ajkd.2009.03.022.
  21. Ridker P.M., MacFadyen J., Cressman M., Glynn R.J. Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial. J. Am. Coll. Cardiol. 2010;55(12):1266–1273. Doi: 10.1016/j.jacc.2010.01.020.
  22. Wanner C., Krane V., Marz W., et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med. 2005;353(3):238–248. Doi: 10.1056/NEJMoa043545.
  23. Tonelli M., Collins D., Robins S., Bloomfield H., Curhan G.C. Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease. Am. J. Kidney Dis. 2004;44(5):832–839.
  24. Tonelli M., Collins D., Robins S., Bloomfield H., Curhan G.C. Veterans’ Affairs High-Density Lipoprotein Intervention Trial I. Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency. Kidney Int. 2004;66(3):1123–1130.
  25. Davis T.M., Ting R., Best J.D., et al. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia. 2011;54(2):280–290. Doi: 10.1007/s00125-010-1951-1.
  26. Zhao Y.Y., Weir M.A., Manno M., et al. New fibrate use and acute renal outcomes in elderly adults: a population-based study. Ann Intern Med. 2012;156(8):560–569. Doi: 10.7326/0003-4819-156-8-201204170-00003.
  27. Ordonez J.D., Hiatt R.A., Killebrew E.J., Fireman B.H. The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int. 1993;44(3):638–642.
  28. Valdivielso P., Moliz M., Valera A., Corrales M.A., Sanchez Chaparro M.A., Gonzalez-Santos P. Atorvastatin in dyslipidaemia of the nephrotic syndrome. Nephrology (Carlton). 2003;8(2):61–64.
  29. Thomas M.E., Harris K.P., Ramaswamy C., et al. Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria. Kidney Int. 1993;44(5):1124–1129.
  30. Kong X., Yuan H., Fan J., Li Z., Wu T., Jiang L. Lipid-lowering agents for nephrotic syndrome. Cochrane Database Syst Rev. 2013;(12):CD005425.
  31. Muso E., Mune M., Hirano T., et al. Immediate therapeutic efficacy of low-density lipoprotein apheresis for drug-resistant nephrotic syndrome: evidence from the short-term results from the POLARIS Study. Clin. Exp. Nephrol. 2014;19(3):379–386. Doi: 10.1007/s10157-014-0996-8.
  32. Muso E. Beneficial effect of LDL-apheresis in refractory nephrotic syndrome. Clin. Exp. Nephrol. 2014;18(2):286–290. Doi: 10.1007/s10157-013-0930-5.
  33. Clement L.C., Mace C., Avila-Casado C., Joles J.A., Kersten S., Chugh S.S. Circulating angiopoietin-like 4 links proteinuria with hypertriglyceridemia in nephrotic syndrome. Nat. Med. 2014;20(1):37–46. Doi: 10.1038/nm.3396.
  34. Sarafidis P.A., Li S., Chen S.C., et al. Hypertension awareness, treatment, and control in chronic kidney disease. Am. J. Med. 2008;121(4):332–340.Doi: 10.1016/j.amjmed.2007.11.025.
  35. Merrill J.P., Giordano C., Heetderks D.R. The role of the kidney in human hypertension. I. Failure of hypertension to develop in the renoprival subject. Am. J. Med. 1961;31:931–940.
  36. Merrill J.P., Schupak E. Mechanisms of hypertension in renoprival man. Can. Med. Assoc. J. 1964;90:328–332.
  37. Pimenta E., Gaddam K.K., Oparil S., et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension. 2009;54(3):475–481.
  38. 38. Slagman M.C., Waanders F., Hemmelder M.H., et al. Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial. BMJ. 2011;343:d4366. Doi: 10.1136/bmj.d4366.
  39. Ozkahya M., Ok E., Cirit M., et al. Regression of left ventricular hypertrophy in haemodialysis patients by ultrafiltration and reduced salt intake without antihypertensive drugs. Nephrol. Dial. Transplant. 1998;13(6):1489–1493.
  40. Dussol B., Moussi-Frances J, Morange S., Somma-Delpero C., Mundler O., Berland Y. A randomized trial of furosemide vs hydrochlorothiazide in patients with chronic renal failure and hypertension. Nephrol. Dial. Transplant. 2005;20(2):349–353. Doi: 10.1093/ndt/gfh650.
  41. Dussol B., Moussi-Frances J., Morange S., Somma-Delpero C., Mundler O., Berland Y. A pilot study comparing furosemide and hydrochlorothiazide in patients with hypertension and stage 4 or 5 chronic kidney disease. J. Clin. Hypertens (Greenwich). 2012;14(1):32–37.
  42. Agarwal R., Sinha A.D., Pappas M.K., Ammous F. Chlorthalidone for poorly controlled hypertension in chronic kidney disease: an interventional pilot study. Am. J. Nephrol. 2014;39(2):171–182. Doi: 10.1159/000358603.
  43. Hou F.F., Zhang X., Zhang G.H., et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N. Engl. J. Med. 2006;354(2):131–140. Doi: 10.1056/NEJMoa053107.
  44. Kendrick J., Teitelbaum I. Strategies for improving long-term survival in peritoneal dialysis patients. Clin. J. Am. Soc. Nephrol. 2010;5(6):1123–1131. Doi: 10.2215/CJN.04300709.
  45. Akbari A., Knoll G., Ferguson D., McCormick B., Davis A., Biyani M. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in peritoneal dialysis: systematic review and meta-analysis of randomized controlled trials. Perit. Dial. Int. 2009;29(5):554–561.
  46. Zannad F., Kessler M., Lehert P., et al. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int. 2006;70(7):1318–1324.
  47. Agarwal R., Sinha A.D., Pappas M.K., Abraham T.N., Tegegne G.G. Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial. Nephrol. Dial. Transplant. 2014;29(3):672–681. Doi: 10.1093/ndt/gft515.
  48. Wright J.T. Jr., Bakris G., Greene T., et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288(19):2421–2431.
  49. Bakris G.L., Fonseca V., Katholi R.E., et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and underhypertension: a randomized controlled trial. JAMA. 2004;292(18):2227–2236.
  50. Cice G., Ferrara L., D’Andrea A., et al. Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J. Am. Coll. Cardiol. 2003;41(9):1438–1444.
  51. Lewis E.J., Hunsicker L.G., Clarke W.R., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 2001;345(12):851–860.
  52. Bakris G.L., Weir M.R., DeQuattro V., McMahon F.G. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int. 1998;54(4):1283–1289.
  53. Smith A.C., Toto R., Bakris G.L. Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. Kidney Int. 1998;54(3):889–896.
  54. Bakris G.L., Sarafidis P.A., Weir M.R., et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet. 2010;375(9721):1173–1181.
  55. Faul C., Amaral A.P., Oskouei B., et al. FGF23 induces left ventricular hypertrophy. J. Clin. Invest. 2011;121:4393–4408.
  56. Muntner P., Jones T.M., Hyre A.D., et al. Association of serum intact parathyroid hormone with lower estimated glomerular filtration rate. Clin. J. Am. Soc. Nephrol. 2009;4:186–194.
  57. Kidney Disease: Improving Global Outcomes Chronic Kidney Disease-Mineral Bone Disorder Working Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int. 2009;76:S1–S130.
  58. Nelson R.G., Tuttle K.R. The new KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and CKD. Blood Purif. 2007;25:112–114.
  59. Levin A., Bakris G.L., Molitch M., et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007;71:31–38.
  60. Kramer H., Berns J.S., Choi M.J., Martin K., Rocco M.V. 25-Hydroxyvitamin D testing and supplementation in CKD: an NKFKDOQI controversies report. Am. J. Kidney Dis. 2014;64:499–509. Doi: 10.1053/j.ajkd.2014.05.018.
  61. Melamed M.L., Astor B., Michos E.D., Hostetter T.H., Powe N.R., Muntner P.25-hydroxyvitamin D levels, race, and the progression of kidney disease. J. Am. Soc. Nephrol. 2009;20:2631–2639.
  62. Fernandez-Juarez G., Luno J., Barrio V., et al. 25 (OH) vitamin D levels and renal disease progression in patients with type 2 diabetic nephropathy and blockade of the renin-angiotensin system. Clin. J. Am. Soc. Nephrol. 2013;8:1870–1876.
  63. Shroff R., Aitkenhead H., Costa N., et al. Normal 25-hydroxyvitamin D levels are associated with less proteinuria and attenuate renal failure progression in children with CKD. J. Am. Soc. Nephrol. 2015;27:314–322.
  64. de Boer I.H., Katz R., Chonchol M., et al. Serum 25-hydroxyvitamin D and change in estimated glomerular filtration rate. Clin. J. Am. Soc. Nephrol. 2011;6:2141–2149.
  65. Rebholz C.M., Grams M.E., Lutsey P.L., et al. Biomarkers of vitamin D status and risk of ESRD. Am. J. Kidney Dis. 2015;67:235–242. Doi: 10,1053 / j.ajkd.2015.08.026.
  66. Li Y.C., Kong J., Wei M., Chen Z.F., Liu S.Q., Cao L.P. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J. Clin. Invest. 2002;110:229–238.
  67. Molina P., Gorriz J.L., Molina M.D., et al. The effect of cholecalciferol for lowering albuminuria in chronic kidney disease: a prospective controlled study. Nephrol. Dial. Transplant. 2014;29:97–109. Doi: 10.1093/ndt/gft360.
  68. 68. Kandula P., Dobre M., Schold J.D., Schreiber M.J. Jr., Mehrotra R., Navaneethan S.D. Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials. Clin. J. Am. Soc. Nephrol. 2011;6:50–62. Doi: 10.2215/CJN.03940510.
  69. Jones G. Expanding role for vitamin D in chronic kidney disease: importance of blood 25-OH-D levels and extra-renal 1alpha-hydroxylase in the classical and nonclassical actions of 1alpha,25-dihydroxyvitamin D(3). Semin Dial. 2007;20:316–324. Doi: 10.1111/j.1525-139X.2007.00302.x.
  70. Palmer S.C., McGregor D.O., Craig J.C., Elder G., Macaskill P., Strippoli G.F. Vitamin D compounds for people with chronic kidney disease requiring dialysis. Cochrane Database Syst. Rev. 2009:CD005633.
  71. Palmer S.C., McGregor D.O., Craig J.C., Elder G., Macaskill P., Strippoli G.F.Vitamin D compounds for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst. Rev. 2009:CD008175.
  72. Wang A.Y., Fang F., Chan J., et al. Effect of paricalcitol on left ventricular mass and function in CKD the OPERA trial. J. Am. Soc. Nephrol. 2014;25:175–186. Doi: 10.1681/ASN.2013010103.
  73. Thadhani R., Appelbaum E., Pritchett Y., et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA. 2012;307:674–684. Doi: 10.1001/jama.2012.120.
  74. Charytan C., Coburn J.W., Chonchol M., et al. Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Am. J. Kidney Dis. 2005;46:58–67.
  75. Chonchol M., Locatelli F., Abboud H.E., et al. A randomized, doubleblind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis. Am. J. Kidney Dis. 2009;53:197–207. Doi: 10.1053/j.ajkd.2008.09.021.
  76. Colloton M., Shatzen E., Miller G., et al. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int. 2005;67:467–476.
  77. Kestenbaum B., Sampson J.N., Rudser K.D., et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J. Am. Soc. Nephrol. 2005;16:520–528.
  78. Menon V., Kopple J.D., Wang X., et al. Effect of a very low-protein diet on outcomes: long-term follow-up of the Modification of Diet in Renal Disease (MDRD) Study. Am. J. Kidney Dis. 2009;53:208–217. Doi: 10.1053/j.ajkd.2008.08.009.
  79. Moe S.M., Zidehsarai M.P., Chambers M.A., et al. Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2011;6:257–264. Doi: 10.2215/CJN.05040610.
  80. Isakova T., Gutierrez O.M., Chang Y., et al. Phosphorus binders and survival on hemodialysis. J. Am. Soc. Nephrol. 2009;20:388–396.
  81. Jamal S.A., Vandermeer B., Raggi P., et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in 268 Melamed et al patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet. 2013;382:1268–1277.
  82. Chen W., Melamed M.L., Abramowitz M.K. Serum bicarbonate and bone mineral density in US adults. Am. J. Kidney Dis. 2015;65:240–248. Doi: 10.1053/j.ajkd.2014.07.007.
  83. Tabatabai L.S., Cummings S.R., Tylavsky F.A., et al. Arterialized venous bicarbonate is associated with lower bone mineral density and an increased rate of bone loss in older men and women. J. Clin. Endocrinol. Metab. 2015;100:1343–1349. Doi: 10.1210/jc.2014-4166.
  84. Phisitkul S., Khanna A., Simoni J., et al. Amelioration of metabolic acidosis in patients with low GFR reduced kidney endothelin production and kidney injury, and better preserved GFR. Kidney Int. 2010;77:617–623.
  85. de Brito-Ashurst I., Varagunam M., Raftery M.J., Yaqoob M.M. Bicarbonate supplementation slows progression of CKD and improves nutritional status. J. Am. Soc. Nephrol. 2009;20:2075–2084.
  86. Goraya N., Simoni J., Jo C., Wesson D.E. Dietary acid reduction with fruits and vegetables or bicarbonate attenuates kidney injury in patients with a moderately reduced glomerular filtration rate due to hypertensive nephropathy. Kidney Int. 2012;81:86–93. Doi: 10.1038/ki.2011.313


Об авторах / Для корреспонденции

Дорофеева Е.Г. – аспирант кафедры госпитальной терапии ФГАОУ ВО РУДН, врач-терапевт ГБУЗ ГКБ № 52 ДЗМ; Москва, Россия.
E-mail: egdorofeeva@bk.ru


Похожие статьи

К содержанию номера

Бионика Медиа